secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001437749-25-036329
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses
--------------------------------------------------------------------------------

- 18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.
- cSCC responses: 6 complete (100% clearance), 2 near complete (>90%), 2 partial (>50%).
- Merkel cell patient had partial response (>50% clearance); no patients showed disease progression.
- No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.
- Highest dose cohort still enrolling; pathology results expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925036329/0001437749-25-036329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925036329/phio20251121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer